Survival and prognostic factors in chondrosarcoma: Results in 115 patients with long-term follow-up

Acta Orthopaedica

Volumn 82, Issue 6, 2011, Pages 749-755

  Andreou, Dimosthenis ^a   Ruppin, Sebastian ^a   Fehlberg, Sebastian ^a   Pink, Daniel ^b   Werner, Mathias ^c   Tunn, Per Ulf ^a  

^a HELIOS KLINIKUM BERLIN BUCH   (Germany)

^b HELIOS Klinikum Bad Saarow   (Germany)

^c HELIOS KLINIKUM EMIL VON BEHRING   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; ALGORITHM; ARTICLE; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHONDROSARCOMA; CLINICAL PROTOCOL; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; TUMOR LOCALIZATION;

ADOLESCENT; ADULT; AGED; BONE NEOPLASMS; CHONDROSARCOMA; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 82255161172     PISSN: 17453674     EISSN: 17453682     Source Type: Journal    
DOI: 10.3109/17453674.2011.636668     Document Type: Article

References (28)

1. Bertoni F, Bacchini P, Hogendoorn P C W. Chondrosarcoma. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone (Eds. Fletcher C D M, Unni K K, Mertens F). IARC Press, Lyon 2002
2. Björnsson J, McLeod R A, Unni K K, Ilstrup D M, Pritchard D J. Primary chondrosarcoma of long bones and limb girdles. Cancer 1998; 83: 2105-19 (Pubitemid 28525392)
3. Bramer J A, Abudu A A, Grimer R J, Carter S R, Tillman R M. Do pathological fractures influence survival and local recurrence rate in bony sarcomas? Eur J Cancer 2007; 43: 1944-51 (Pubitemid 47284871)
4. Brennan M F. The enigma of local recurrence. The Society of Surgical Oncology. Ann Surg Oncol 1997; 4: 1-12 (Pubitemid 127727865)
5. Brennan M F. Local recurrence in soft tissue sarcoma: More about the tumor, less about the surgeon. Ann Surg Oncol 2007; 14: 1528-9 (Pubitemid 46791014)
6. Campanacci M. Bone and soft tissue tumors, 2nd edn. Piccin Nuova Libraria, Padova 1999
7. Dahlin D C, Henderson E D. Chondrosarcoma, a surgical and pathological problem; review of 212 cases. J Bone Joint Surg (Am) 1956; 38: 1025-38
8. Delaney T F, Liebsch N J, Pedlow F X, Adams J, Dean S, Yeap B Y, McManus P, Rosenberg A E, Nielsen G P, Harmon D C, Spiro I J, Raskin K A, Suit H D, Yoon S S, Hornicek F J. Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. Int J Radiat Oncol Biol Phys 2009; 74: 732-9
9. Evans H L, Ayala A G, Romsdahl M M. Prognostic factors in chondrosarcoma of bone: A clinicopathologic analysis with emphasis on histologic grading. Cancer 1977; 40: 818-31 (Pubitemid 8177905)
10. Fiorenza F, Abudu A, Grimer R J, Carter S R, Tillman R M, Ayoub K, Mangham D C, Davies A M. Risk factors for survival and local control in chondrosarcoma of bone. J Bone Joint Surg (Br) 2002; 84: 93-9 (Pubitemid 34105631)
11. Gelderblom H, Hogendoorn P C, Dijkstra S D, van Rijswijk C S, Krol A D, Taminiau A H, Bovée J V. The clinical approach towards chondrosarcoma. Oncologist 2008; 13: 320-9 (Pubitemid 351679908)
12. Gitelis S, Bertoni F, Picci P, Campanacci M. Chondrosarcoma of bone. The experience at the Istituto Ortopedico Rizzoli. J Bone Joint Surg (Am) 1981; 63: 1248-57 (Pubitemid 11022301)
13. Gouin F, Ory B, Rédini F, Heymann D. Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival. Int J Cancer 2006; 119: 980-4 (Pubitemid 44116903)
14. Greene F L, Page D L, Fleming I D, Fritz A, Balch C, Haller D, Morrow M (eds.). AJCC Cancer Staging Manual. Springer-Verlag, New York 2002
15. Gronchi A, Miceli R, Fiore M, Collini P, Lozza L, Grosso F, Mariani L, Casali P G. Extremity soft tissue sarcoma: Adding to the prognostic meaning of local failure. Ann Surg Oncol 2007; 14 (5): 1583-90 (Pubitemid 46791007)
16. Healey J H, Lane J M. Chondrosarcoma. Clin Orthop 1986; (204): 119-29 (Pubitemid 16069366)
17. Heck R K Jr, Stacy G S, Flaherty M J, Montag A G, Peabody T D, Simon M A. A comparison study of staging systems for bone sarcomas. Clin Orthop 2003; (415): 64-71 (Pubitemid 37329041)
18. Kempf-Bielack B, Bielack S S, Jürgens H, Branscheid D, Berdel W E, Exner G U, Göbel U, Helmke K, Jundt G, Kabisch H, Kevric M, Klingebiel T, Kotz R, Maas R, Schwarz R, Semik M, Treuner J, Zoubek A, Winkler K. Osteosarcoma relapse after combined modality therapy: An analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005; 23: 559-68 (Pubitemid 46224233)
19. Klenke F M, Abdollahi A, Bertl E, Gebhard M M, Ewerbeck V, Huber P E, Sckell A. Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo. BMC Cancer 2007; 7: 49
20. Lee F Y, Mankin H J, Fondren G, Gebhardt M C, Springfield D S, Rosenberg A E, Jennings L C. Chondrosarcoma of bone: An assessment of outcome. J Bone Joint Surg (Am) 1999; 81: 326-38 (Pubitemid 29153210)
21. Leerapun T, Hugate R R, Inwards C Y, Scully S P, Sim F H. Surgical management of conventional grade I chondrosarcoma of long bones. Clin Orthop 2007; (463): 166-72 (Pubitemid 47585267)
22. Morioka H, Weissbach L, Vogel T, Nielsen G P, Faircloth G T, Shao L, Hornicek F J. Antiangiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis. Clin Cancer Res 2003; 9: 1211-7 (Pubitemid 36323731)
23. Pritchard D J, Lunke R J, Taylor W F, Dahlin D C, Medley B E. Chondrosarcoma: A clinicopathologic and statistical analysis. Cancer 1980; 45: 149-57 (Pubitemid 10214969)
24. Rizzo M, Ghert M A, Harrelson J M, Scully S P. Chondrosarcoma of bone: Analysis of 108 cases and evaluation for predictors of outcome. Clin Orthop 2001; (391): 224-33 (Pubitemid 32954068)
25. Schrage Y M, Briaire-de Bruijn I H, de Miranda N F, van Oosterwijk J, Taminiau A H, van Wezel T, Hogendoorn P C, Bovée J V. Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment. Cancer Res 2009; 69: 6216-22
26. Schrage Y M, Machado I, Meijer D, Briaire-de Bruijn I, van den Akker B E, Taminiau A H, Kalinski T, Llombart-Bosch A, Bovée J V. COX-2 expression in chondrosarcoma: A role for celecoxib treatment? Eur J Cancer 2010; 46: 616-24
27. Schwab J H, Wenger D, Unni K, Sim F H. Does local recurrence impact survival in low-grade chondrosarcoma of the long bones? Clin Orthop 2007; 462: 175-80 (Pubitemid 47367860)
28. Streitbürger A, Ahrens H, Balke M, Buerger H, Winkelmann W, Gosheger G, Hardes J. Grade I chondrosarcoma of bone: The Münster experience. J Cancer Res Clin Oncol 2009; 135: 543-50.